BIP Wealth LLC Acquires 8,785 Shares of Amgen Inc. $AMGN

BIP Wealth LLC raised its holdings in Amgen Inc. (NASDAQ:AMGN) by 808.2% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 9,872 shares of the medical research company’s stock after buying an additional 8,785 shares during the period. BIP Wealth LLC’s holdings in Amgen were worth $3,231,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Board of the Pension Protection Fund bought a new stake in Amgen in the fourth quarter valued at approximately $26,000. Olistico Wealth LLC bought a new stake in Amgen in the fourth quarter valued at approximately $33,000. Holos Integrated Wealth LLC bought a new stake in Amgen in the fourth quarter valued at approximately $37,000. Cloud Capital Management LLC acquired a new position in shares of Amgen in the third quarter valued at approximately $34,000. Finally, Saranac Partners Ltd acquired a new position in shares of Amgen in the third quarter valued at approximately $37,000. Institutional investors own 76.50% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on AMGN. UBS Group upped their target price on Amgen from $380.00 to $390.00 and gave the company a “buy” rating in a research report on Monday, January 26th. Royal Bank Of Canada upped their target price on Amgen from $360.00 to $370.00 and gave the company an “outperform” rating in a research report on Tuesday. Deutsche Bank Aktiengesellschaft upped their target price on Amgen from $285.00 to $295.00 and gave the company a “hold” rating in a research report on Thursday, February 5th. Truist Financial upped their target price on Amgen from $318.00 to $319.00 and gave the company a “hold” rating in a research report on Thursday, January 8th. Finally, The Goldman Sachs Group upped their target price on Amgen from $403.00 to $415.00 and gave the company a “buy” rating in a research report on Wednesday, February 4th. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, thirteen have given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $355.00.

Amgen Trading Down 0.8%

Shares of NASDAQ:AMGN opened at $340.00 on Wednesday. The company has a market capitalization of $183.28 billion, a P/E ratio of 23.89, a P/E/G ratio of 3.45 and a beta of 0.47. Amgen Inc. has a 1 year low of $261.43 and a 1 year high of $391.29. The company has a debt-to-equity ratio of 5.78, a current ratio of 1.14 and a quick ratio of 0.90. The business’s 50 day simple moving average is $363.28 and its 200 day simple moving average is $334.04.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.76 by $0.53. The business had revenue of $9.87 billion for the quarter, compared to the consensus estimate of $9.46 billion. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The firm’s quarterly revenue was up 8.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, research analysts anticipate that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be given a dividend of $2.52 per share. The ex-dividend date of this dividend is Friday, May 15th. This represents a $10.08 dividend on an annualized basis and a yield of 3.0%. Amgen’s dividend payout ratio is currently 70.84%.

Trending Headlines about Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Phase‑3 win — Amgen’s subcutaneous TEPEZZA met primary and key secondary endpoints (77% proptosis response, clinically meaningful ≥3 mm reduction), matching IV efficacy and offering faster dosing that could broaden access. AMGN’s Subcutaneous Tepezza Scores Phase III Win in Thyroid Eye Disease
• Positive Sentiment: Analyst support — RBC Capital raised its price target to $370 and kept an Outperform rating, signaling institutional confidence in Amgen’s commercial prospects for TEPEZZA. RBC raises AMGN price target to $370
• Neutral Sentiment: Market interest rising — Retail and institutional attention to AMGN has increased (search/coverage pieces from Zacks/Yahoo), which can amplify intraday moves but is not a directional catalyst by itself. Investors Heavily Search Amgen Inc. (AMGN)
• Neutral Sentiment: Competitive read — Stifel notes Amgen’s topline compares favorably to Viridian’s data on absolute and placebo‑adjusted response, but highlights that Viridian’s subcutaneous injection profile could still differentiate in the market—keeping competitive uncertainty alive. Stifel sees path towards differentiation for Viridian after Amgen data
• Negative Sentiment: Stock weakness despite data — Multiple reports note Amgen shares fell intraday even after the positive TEPEZZA readout; investors may be taking profits, weighing execution/commercialization risk, or reacting to remaining competitive questions. Amgen Posts 77% Response In Thyroid Eye Disease Study

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.